Abivax Aktie
| 8,03EUR | -0,06EUR | -0,74% |
WKN DE: A14UQC / ISIN: FR0012333284
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 62,48 |
| TCG Crossover Management LLC | 9,45 |
| Sofinnova Partners SAS | 8,32 |
| Truffle Capital SAS | 7,69 |
| Deep Track Capital LP | 4,94 |
| VHCP Management LLC | 4,13 |
| DNCA Invest - Beyond Global Leaders | 1,18 |
| Paolo Rampulla | 1,17 |
| HBM Healthcare Investments AG | 1,11 |
| Pictet - Biotech | 0,86 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 26 | 27 | 26 | 24 | 61 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 17 | 37 | 75 | 48 | 286 |
| Summe Anlagevermögen | 35 | 35 | 36 | 25 | 41 |
| Summe Aktiva | 52 | 71 | 110 | 73 | 327 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 21 | 34 | 53 | 47 | 55 |
| Summe Fremdkapital | 40 | 67 | 82 | 71 | 131 |
| Summe Eigenkapital | 12 | 5 | 29 | 2 | 196 |
| Summe Passiva | 52 | 71 | 110 | 73 | 327 |
Adresse
| 7-11 Boulevard Haussmann, 75009 Paris | |
| Telefon | +33 (1) 53-83-09-63 |
| Internet | http://www.abivax.com |
Management
|
Camilla Soenderby
Director |
|
Christopher Rabbat
Head-Medical Affairs & Vice President |
|
Corinna Zur Bonsen-Thomas
Independent Director |
|
David Zhang
Chief Strategy Officer |
|
Didier Blondel
Chief Financial Officer, Secretary & EVP |
|
Didier Scherrer
Chief Scientific Officer |
|
Fabio Cataldi
Chief Medical Officer |
|
Hema Keshava
Senior Vice President-Finance |
|
Ida Hatoum
Chief People & Compliance Officer |
|
June H Lee
Director |
|
Kinam Hong
Director |
|
Marc M. P. de Garidel
Chief Executive Officer |
|
Patrick Malloy
Senior Vice President-Investor Relations |
|
Philippe Pouletty
Director |
|
Pierre Courteille
Chief Business Officer |
|
Sharon Skare
Head-Clinical Operations & Vice President |
|
Sylvie Louise Grégoire
Chairman |
|
Troy A. Ignelzi
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
